Phase 1 study of IDOR-1117-2520
Latest Information Update: 28 Apr 2023
At a glance
- Drugs IDOR 11172520 (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
Most Recent Events
- 28 Apr 2023 New trial record
Latest Information Update: 28 Apr 2023